At 3 years, COLUMVI + GemOx continues to deliver a sustained overall survival benefit with a manageable safety profile. As the first and only off‑the‑shelf therapy with curative potential in 2L DLBCL, COLUMVI + GemOx is now recommended by EHA and ESMO Guidelines with the highest category of evidence (I,A).1-6
COLUMVI in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).1
COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.1
COLUMVI + GemOx
Curative
potential
with
sustained OS
in 2L DLBCL2
At 3 years, COLUMVI + GemOx showed long-term survival benefit (median OS NE; 95% CI: 22.8, NE) vs R-GemOx (median OS 14.4 months; 95% CI: 10.3, 26.8).2
EHA & ESMO
GUIDELINES recommended
for 2L DLBCL4,5
COLUMVI + GemOx is now recommended by EHA and ESMO Guidelines with the highest category of evidence (I,A) in 2L treatment of patients with DLBCL not intended to proceed to CAR-T therapy in early relapse or ASCT in late relapse.4,5
Deep
remission
regardless
of relapse
time in 2L
DLBCL3
At 3 years, COLUMVI + GemOx demonstrated sustained remission in both early relapse patients (56% CR, n=64) and late relapse patients (84%, n=31).3
COLUMVI + GemOx treatment was well tolerated and the safety profile is consistent with the known risk of the individual drugs1,4
CRS associated with COLUMVI + GemOx was generally low grade, primarily occurred in Cycle 1, and typically resolved within 24 hours.
COLUMVI + GemOx more than tripled the median PFS in 2L DLBCL2
At 3 years, COLUMVI + GemOx sustained PFS in 2L DLBCL (median PFS 20.4 months; 95% CI 9.2, NE) vs R-GemOx (median PFS 5.5 months; 95% CI 2.6, 9.7).2
